Otros idiomas AnaptysBio, Inc.

Acciones

ANAB

US0327241065

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
25,07 ^USD	-1,57 %		+7,09 %	+17,04 %

09/05	AnaptysBio, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
09/05	Anaptys anuncia resultados positivos de primera línea del ensayo clínico de fase 3 Gemini-2 de imsidolimab (IL-36R) en la psoriasis pustulosa generalizada (GPP)	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update	09/05
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)	09/05
Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	09/05
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties	09/05
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	18/03
North American Morning Briefing : Stock Futures -2-	13/03
AnaptysBio Shares Jump on Upgrade by Wedbush	12/03
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	11/03
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	29/02
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	29/02
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	16/02
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	31/01
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	31/01
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	18/12
GSK : l'UE approuve Jemperli dans le cancer de l'endomètre	11/12
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	27/11
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals	27/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas AnaptysBio, Inc.

Acciones

ANAB

US0327241065

Otros idiomas

Filtros